glp-1 receptor agonist brand names Agonists Examples: Which One Wins? GLP-1 Receptor Agonist - ReliableRxPharmacy

Available from: _Product_Information/human/002735/WC500165117.pdf

doi: 10.2337/diabetes.54.7.2212 [DOI] [PubMed] [Google Scholar] 154

In 2022, a modified version of the GLP-1/GIP dual agonist, tirzepatide (Zepbound), developed by Eli Lilly induced an average weight loss of 21% in humans with obesity and 15% weight loss in obese patients with diabetes (1)

Chronic low-grade inflammation is increasingly recognised as a key contributor to numerous conditions, including cardiovascular disease, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), and certain autoimmune disorders

Bone health following bariatric surgery: implications for management strategies to attenuate bone loss

Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential